The contingent workforce is no longer a peripheral strategy for talent. By 2026, contract, freelance, and project-based professionals will account for more than 40% of the workforce in many large life sciences organisations, and the trajectory is still upward. Add in tighter regulatory expectations, the wave of post-Novo Nordisk restructurings reshaping headcount, and the FDA's own internal cutbacks lengthening review timelines, and the question for most pharma, biotech, and medtech leaders is no longer whether to professionalise contingent hiring; it is whether a Managed Service Provider model is the right way to do it.
